Table 1.
Compound (abbreviation) | Target | Process | Concentration |
---|---|---|---|
HDAC inhibitor 4b (4b)a | HDAC3 | Histone acetylation | 5 μM |
Sodium butyrate (NaB) | HDAC class I | Histone acetylation | 0.5 mM |
Tranylcypromine, Parnate (Par) | LSD1 | Histone H3K4 methylation | 4 μM |
Tubastatin A (TubA) | HDAC6 | Histone acetylation | 5 μM |
RG108 (RG) | DNMT | CpG methylation | 5 μM |
BIX01294 (BIX) | G9a | Histone H3K9 methylation | 4 μM |
Epi-ML (EML)b | Multiple | Multiple targets | 5 μM |
DMSO | Control | — | — |
Only compounds that resulted in successful establishment of iPSC clones are shown.
HDACi 4b has been demonstrated to increase expression of the FXN gene in FRDA lymphoid cells and neurons, but not in FRDA fibroblasts or iPSCs.
Epigenetic Multiple Ligand (Epi-ML; Calbiochem) is a cell-permeable bis-arylidene compound that inhibits several mammalian histone-modifying enzymes, including SET7, PRMT1, p300/CBP, and SIRT1/2.
DMSO, dimethyl sulfoxide; EML, Epigenetic Multiple Ligand; FRDA, Friedreich's ataxia; FXN, frataxin; HDACi, histone deacetylase inhibitors; iPSCs, induced pluripotent stem cells.